Back

Discussant review - MIRACLE

11 May 2024 (13:53 - 13:57)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials: medical therapy Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Milton Packer

Baylor University Medical Center, Dallas (United States of America)

9 More presentations in this session

Presentation thumbnail
A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure
Professor C. Lam (Singapore, SG)
Slides Video
Presentation thumbnail
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
Professor J. Udelson (Boston, US)
Slides Video
Presentation thumbnail
Discussant review - CARDINAL HF
Associate Professor A. Bohm (Bratislava, SK)
Slides Video
Presentation thumbnail
Readily available urinary sodium analysis in patients with acute decompensate Heart Failure
Doctor E. Meekers (Genk, BE)
Slides Video
Presentation thumbnail
Discussant review - EASY-HF
Doctor P. Pellicori (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials: medical therapy
Video

The Event

Event poster

Heart Failure 2024

11 May 2024 13:53 CET
You may be interested in
thumbnail
Congress Presentation
nsMRAs: what emerging trials tell us about the future of heart failure therapy
thumbnail
Congress Presentation
Mineralocorticoid receptor antagonist drugs in HFpEF
thumbnail
Congress Presentation
Non-steroidal mineralocorticoid receptor antagonists (MRAs): standard therapy for HFpEF?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources